On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) in individuals 18 years of age and older.

CAPVAXIVE is specifically designed to help protect adults against the serotypes that cause the majority of invasive pneumococcal disease (IPD) cases.